




RealRate

PHARMACEUTICAL 2013

Ernexa Therapeutics Inc
Rank 72 of 218



The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 152% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is 293%, being 73% points above the market average of 220%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	4,229	Assets	12,656
Cost of Goods Sold	0	Liabilities	4,762
Intangible Assets	1,844	Expenses	25,043
Liabilities, Current	3,388	Revenues	24,064
Liabilities, Non-Current	170	Stockholders Equity	7,894
Other Assets	2,800	Net Income	-995
Other Compr. Net Income	46	Comprehensive Net Income	-972
Other Expenses	6,795	BaseVar	33,294
Other Liabilities	1,204	ECR before LimitedLiability	186%
Other Net Income	-16	Economic Capital Ratio	293%
Other Revenues	24,064		
Property and Equipment	3,783		
Research and Development	0		
Selling, General and Administrative Expense	18,248		